Venous thrombosis and predictors of relapse in eosinophil-related diseases.

Autor:	Réau V; Department of Internal and Geriatric Medicine, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France.; National Reference Center for Hypereosinophilic Syndromes, CEREO, France., Vallée A; Department of Clinical Research and Innovation (DRCI), Hôpital Foch, 92150, Suresnes, France., Terrier B; Department of Internal Medicine, National Referral Center for Systemic and Autoimmune Diseases, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France., Plessier A; Department of Hepatology, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris, Clichy, France., Abisror N; Department of Internal Medicine, Saint Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France., Ackermann F; National Reference Center for Hypereosinophilic Syndromes, CEREO, France.; Department of Internal Medicine, Hôpital Foch, 40, rue Worth, 92151, Suresnes Cedex, France., Benainous R; Department of Internal Medicine, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, Bobigny, France., Bohelay G; Department of Dermatology, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, Bobigny, France., Chabi-Charvillat ML; Department of Radiology, Foch Hospital, Suresnes, France., Cornec D; Department of Rheumatology, Brest University Hospital, Brest, France., Desbois AC; Department of Internal Medicine, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France., Faguer S; Department of Nephrology, Toulouse University Hospital, Toulouse, France., Freymond N; Department of Pulmonology, Lyon University Hospital, Lyon, France., Gaillet A; National Reference Center for Hypereosinophilic Syndromes, CEREO, France.; Department of Internal Medicine, Hôpital Foch, 40, rue Worth, 92151, Suresnes Cedex, France., Hamidou M; Department of Internal Medicine, Hôtel-Dieu University Hospital, Nantes, France., Killian M; Department of Internal Medicine, Saint-Etienne University Hospital, Saint-Etienne, France., Le Jeune S; Department of Internal Medicine, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, Bobigny, France., Marchetti A; Department of Dermatology, Lyon-Sud Hospital, Pierre-Bénite, France., Meyer G; Pulmonology and Intensive Care Service, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France., Osorio-Perez F; Department of Internal Medicine, Dax-Côte D'Argent Hospital, Dax, France., Panel K; National Reference Center for Hypereosinophilic Syndromes, CEREO, France.; Department of Internal Medicine, Hôpital Foch, 40, rue Worth, 92151, Suresnes Cedex, France., Rautou PE; Department of Hepatology, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris, Clichy, France., Rohmer J; National Reference Center for Hypereosinophilic Syndromes, CEREO, France.; Department of Internal Medicine, Hôpital Foch, 40, rue Worth, 92151, Suresnes Cedex, France., Simon N; Department of Internal Medicine, Grenoble Alpes University Hospital, Grenoble, France., Tcherakian C; Department of Pulmonology, Foch Hospital, Suresnes, France., Vasse M; Department of Clinical Biology, Foch Hospital, Suresnes, France.; UMR-S INSERM 1176, Université Paris-Saclay, Le Kremlin-Bicêtre, France., Zuelgaray E; Department of Dermatology, Saint Louis, Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France., Lefevre G; National Reference Center for Hypereosinophilic Syndromes, CEREO, France.; Department of Internal Medicine, Lille University Hospital, Lille, France., Kahn JE; National Reference Center for Hypereosinophilic Syndromes, CEREO, France.; Department of Internal Medicine, Ambroise Paré Hospital, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France., Groh M; National Reference Center for Hypereosinophilic Syndromes, CEREO, France. m.groh@hopital-foch.com.; Department of Internal Medicine, Hôpital Foch, 40, rue Worth, 92151, Suresnes Cedex, France. m.groh@hopital-foch.com.
Jazyk:	angličtina
Zdroj:	Scientific reports [Sci Rep] 2021 Mar 18; Vol. 11 (1), pp. 6388. Date of Electronic Publication: 2021 Mar 18.
DOI:	10.1038/s41598-021-85852-9
Abstrakt:	Eosinophils have widespread procoagulant effects. Eosinophilic cardiovascular toxicity mostly consists of endomyocardial damage or eosinophilic vasculitis, while reported cases of venous thrombosis (VT) are scarce. We aimed to report on the clinical features and treatment outcomes of patients with unexplained VT and eosinophilia, and to identify predictors of relapse. This retrospective, multicenter, observational study included patients aged over 15 years with VT, concomitant blood eosinophilia ≥ 1G/L and without any other moderate-to-strong contributing factors for VT. Fifty-four patients were included. VT was the initial manifestation of eosinophil-related disease in 29 (54%) patients and included pulmonary embolism (52%), deep venous thrombosis (37%), hepatic (11%) and portal vein (9%) thromboses. The median [IQR] absolute eosinophil count at VT onset was 3.3G/L [1.6-7.4]. Underlying eosinophil-related diseases included FIP1L1-PDGFRA-associated chronic myeloid neoplasm (n = 4), Eosinophilic Granulomatosis with Polyangiitis (n = 9), lymphocytic (n = 1) and idiopathic (n = 29) variants of hypereosinophilic syndrome. After a median [IQR] follow-up of 24 [10-62] months, 7 (13%) patients had a recurrence of VT. In multivariate analysis, persistent eosinophilia was the sole variable associated with a shorter time to VT relapse (HR 7.48; CI95% [1.94-29.47]; p = 0.015). Long-term normalization of eosinophil count could prevent the recurrence of VT in a subset of patients with unexplained VT and eosinophilia ≥ 1G/L.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF